What Is Dengue Hemorrhagic Fever?

Topaz

Dengue fever and dengue hemorrhagic fever

[Etiology]

Dengue virus belongs to the flavivirus genus Flavivirus. It is an enveloped, single-stranded positive-strand RNA virus. It is dumbbell-shaped, rod-shaped, or spherical with a spherical diameter of 50 nm. The core of the dengue virus is a 20-sided stereosymmetric virus particle composed of RNA and protein, and the outer layer is an envelope composed of glycoprotein. Viral genes encode 3 structural proteins and 7

Mosquito control and mosquito prevention are the main measures to prevent dengue fever and dengue hemorrhagic fever. For details, please refer to Chapter 13, Section 2, "Malaria", and Chapter 8, Section "Jepp Encephalitis". Mosquito killing is mainly to kill mosquito breeding grounds. Aedes mosquitoes often spawn in small stagnant water to breed. For example, pots, tanks, tanks, caves, etc. can be turned over, inverted, flattened depressions, and cleared trenches. Spray various organophosphate insecticides to minimize mosquito density. Suspect patients should be medically observed. Patients should be isolated in a ward with screens and screens for at least 5 days. Vaccination is the most effective measure to prevent dengue fever, but there is currently no safe and effective vaccine for clinical use. Because monovalent vaccination may produce enhanced antibodies and may increase the incidence of dengue hemorrhagic fever, most of the current vaccine developments are multivalent vaccines. The types of vaccines currently under development in the world include: Type 4 mixed live attenuated vaccines, which have entered clinical trials and have shown satisfactory immune protection; polytype subunit vaccines, polytype chimeric live attenuated vaccines, dengue fever DNA vaccines have also shown some protection in animal experiments.

references

1. Ye Jianjie, Hu Liming, Chu Shaojie. Dengue fever epidemiology. Chinese Journal of Preventive Medicine, 2007, 8 (4): 506-508.

2. Wang Jian, Hong Wenting, Zhang Fuchun. Comparative analysis of clinical characteristics of three serotypes of dengue patients in Guangzhou. China Tropical Medicine, 2007, 7 (10): 1760-1762.

3 .de Oliveira Poersch C, Pavoni DP, Queiroz MH, et al. Dengue virus infections: comparison of methods f or diagnosing the acute disease. J Clin Virol, 2005, 32: 272-277.

4.Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. AmJ Trop Med Hyg, 2008, 78 (3): 426-433.

^[1]